NCT03602235View on ClinicalTrials.gov

High Dose Ascorbic Acid for Plasma Cell Disorders

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

March 5, 2019

Primary Completion Date

July 1, 2024

Study Completion Date

September 3, 2025

Conditions
Multiple Myeloma
Interventions
OTHER

Ascorbate

Ascorbate is in the vitamin drug class

DRUG

Melphalan

Melphalan is an alkylating agent coupled to an amino acid

Trial Locations (1)

52242

University of Iowa Hospitals and Clinics, Iowa City

All Listed Sponsors
collaborator

University of Iowa

OTHER

lead

Christopher Strouse

OTHER

NCT03602235 - High Dose Ascorbic Acid for Plasma Cell Disorders | Biotech Hunter | Biotech Hunter